Flecainide
Unchecked
Flecainide
Tambocor (US brand discontinued)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Atrial fibrillation rhythm control (pill-in-pocket or chronic)0, Recurrent supraventricular tachycardia in structurally normal hearts0, Catecholaminergic polymorphic VT (off-label)0
Pharmacy
Starting dose
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion
Preparations
50, 100, 150 mg tablets
US FDA Max
400 mg/d
Pharmacology
Routes
Oral
Onset
AF conversion within hours of single PO dose
Duration
12 hours
Half-life
~14 hours (adults); longer in elderly and renal impairment[1]
Bioavailability
~90% (oral)[1]
Pregnancy
Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.[citation needed]
Legal status
Purported mechanism
Flecainide is a potent voltage-gated sodium channel blocker (class IC); it slows phase 0 depolarization with strong use-dependence and slow dissociation kinetics, prolonging conduction and the refractory period particularly in atrial tissue and accessory pathways.0 Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate[1].
References
[edit | edit source]- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, flecainide acetate, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018830s056lbl.pdf